Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 47
Filter
1.
Eur J Clin Invest ; 52(8): e13778, 2022 Aug.
Article in English | MEDLINE | ID: mdl-35342952

ABSTRACT

BACKGROUND: Behçet disease (BD) is a systemic vasculitis. In addition to the mucocutaneous lesions, the vascular injury of pathophysiology in BD is theoretically correlated with cardiovascular diseases. This study aimed to elucidate the association of BD with ischaemic heart diseases (IHDs) and stroke. METHODS: A systematic search of PubMed, Embase, Web of Science and Cochrane Library databases was performed for all relevant observational studies from database inception until 10 July 2021. No language restriction was applied. A random-effects model was used for meta-analysis. RESULTS: A total of six observational studies consisting of three cohort studies, two cross-sectional studies and one study with both study designs were adopted in the meta-analysis. The numbers of patients with BD and healthy controls were 9,813 and 41,802, respectively. The pooled analysis demonstrated no significant association between BD and IHD. By contrast, we found that patients with BD had a significantly higher risk of stroke (adjusted hazard ratio, 2.083; 95% confidence interval, 1.339-3.240; p = 0.001) than healthy controls. We observed substantial heterogeneity across studies in few meta-analyses, but no significant publication bias was detected in any of the meta-analyses. CONCLUSIONS: BD was significantly associated with stroke but not IHD. Physicians should be aware of possible vascular and neurological complications during care of patients with BD.


Subject(s)
Behcet Syndrome , Myocardial Ischemia , Stroke , Behcet Syndrome/complications , Behcet Syndrome/epidemiology , Cross-Sectional Studies , Humans , Myocardial Ischemia/epidemiology , Myocardial Ischemia/etiology , Risk Factors , Stroke/complications , Stroke/etiology
2.
J Am Acad Dermatol ; 82(3): 596-605, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31499151

ABSTRACT

BACKGROUND: The association between dyslipidemia and xanthelasma palpebrarum (XP) remains controversial, and no definite evidence has indicated atherosclerosis risk in patients with XP. OBJECTIVE: The present study was a systematic review and meta-analysis to elucidate the association of serum lipid profiles and risk of atherosclerotic diseases with XP. METHODS: We systematically searched for the eligible comparative studies published before April 15, 2019, in the databases of PubMed, Web of Science, Embase, and Cochrane Library. A random-effects model was used to calculate the standard mean difference with 95% confidence interval for each pooled estimate. RESULTS: The qualitative analyses included 15 case-control studies with 854 patients with XP. Compared with the controls, the patients with XP had significantly higher serum levels of total cholesterol and low-density lipoproteins, significantly higher apolipoprotein B levels, and relatively lower apolipoprotein A1 levels, and the carotid intima-media thickness was significantly higher. CONCLUSION: Patients with XP had significantly higher serum levels of atherogenic low-density lipoproteins and bore significantly higher risk of atherosclerosis than the controls. Careful monitoring and targeted intervention for prevention of cardiovascular diseases is essential for these patients.


Subject(s)
Atherosclerosis/epidemiology , Eyelids/pathology , Lipoproteins, LDL/blood , Xanthomatosis/complications , Atherosclerosis/blood , Atherosclerosis/etiology , Atherosclerosis/prevention & control , Case-Control Studies , Humans , Risk Factors , Xanthomatosis/blood , Xanthomatosis/pathology
5.
Aesthet Surg J ; 39(7): NP279-NP287, 2019 06 21.
Article in English | MEDLINE | ID: mdl-30809666

ABSTRACT

BACKGROUND: Acne scars are common and challenging clinical complications of acne vulgaris. Ablative fractional carbon dioxide (CO2) laser is a well-established treatment for acne scars; however, some postlaser adverse effects have been noted. Autologous platelet-rich plasma (PRP) can improve tissue regeneration. Several studies have investigated the efficacy of combination therapy of CO2 laser and PRP for acne scars. OBJECTIVES: The authors sought to conduct a meta-analysis of the efficacy of PRP combined with ablative fractional CO2 laser for treating acne scars by examining clinical trial results. METHODS: A systematic review was performed by searching PubMed, Embase, Cochrane Library, and Web of Science, and a meta-analysis was conducted to assess the clinical outcomes after combination therapy of PRP and ablative fractional CO2 laser compared with laser alone. RESULTS: We identified 4 eligible studies for the meta-analysis, including 3 randomized controlled trials. Our results demonstrated that clinical improvement after combination therapy was significantly higher than that after laser alone (odds ratio = 2.992, P = 0.001). Regarding major side effects, patients who underwent combination therapy experienced significantly shorter duration of crust compared with CO2 laser alone (standard mean difference = -1.140, P < 0.001); relatively shorter durations of erythema and edema were also noted after combination therapy. Furthermore, patient satisfaction rates were significantly higher after combination therapy than after laser alone (odds ratio = 3.169, P = 0.002). CONCLUSIONS: The combination of autologous PRP and ablative fractional CO2 laser has synergistic positive effects on the clinical outcomes for acne scars and can accelerate the recovery of laser-damaged skin.


Subject(s)
Acne Vulgaris/complications , Blood Transfusion, Autologous/methods , Cicatrix/therapy , Lasers, Gas/therapeutic use , Platelet-Rich Plasma , Cicatrix/etiology , Combined Modality Therapy/adverse effects , Combined Modality Therapy/methods , Edema/etiology , Edema/prevention & control , Erythema/etiology , Erythema/prevention & control , Humans , Lasers, Gas/adverse effects , Patient Satisfaction , Skin/radiation effects , Treatment Outcome
6.
Biochim Biophys Acta Mol Cell Res ; 1864(4): 687-696, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28131718

ABSTRACT

Erythropoietin (EPO) and GM-CSF are involved in erythropoiesis, while TGF-ß inhibits proliferation but potentiates differentiation of erythroblasts. Since Syk inhibitor may induce anemia side effect in clinic, here we investigated the role of Syk in the biological actions of EPO and GM-CSF in erythropoiesis. In human erythroleukemia cell line TF-1, Syk inhibitor R406 exerts an enhancement effect with TGF-ß to decrease cell viability, either in the absence or presence of EPO or GM-CSF. Such effect of R406 results from the reduced cell cycle progression and increased cell apoptosis. Notably, unlike Syk, Src family kinases are not involved in the viability control of TF-1 cells. Signaling studies showed that Syk is required for STAT5 and ERK activation induced by EPO, and Akt and ERK activation induced by GM-CSF. Nevertheless, R406 does not change the Smad2/3 signal caused by TGF-ß, and TGF-ß neither affects above signal pathways of EPO and GM-CSF. Of note, Syk is constitutively associated with EPOR in plasma membrane and can bind to STAT5 at active status upon EPO stimulation. Furthermore, EPO-induced hemoglobin γ expression was reduced by R406. In BFU-E and CFU-E colony formation assays in Syk-deficient erythroid progenitor cells, we confirmed the essential role of Syk in erythropoiesis mediated by EPO. Taken together, Syk is a novel upstream signaling molecule of EPOR, and contributes to erythroblast proliferation, survival and differentiation.


Subject(s)
Erythropoiesis/genetics , Erythropoietin/pharmacology , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Leukocytes/drug effects , Syk Kinase/genetics , Transforming Growth Factor beta/genetics , Animals , Apoptosis/drug effects , Cell Cycle Checkpoints/drug effects , Cell Line, Tumor , Cell Survival/drug effects , Fetus , Gene Expression Regulation , Humans , Leukocytes/cytology , Leukocytes/metabolism , Mice , Mice, Inbred C57BL , Oxazines/pharmacology , Protein Kinase Inhibitors/pharmacology , Proto-Oncogene Proteins c-akt/genetics , Proto-Oncogene Proteins c-akt/metabolism , Pyridines/pharmacology , Receptors, Erythropoietin/genetics , Receptors, Erythropoietin/metabolism , STAT5 Transcription Factor/genetics , STAT5 Transcription Factor/metabolism , Signal Transduction , Syk Kinase/metabolism , Transforming Growth Factor beta/metabolism
10.
CMAJ ; 194(29): E1036, 2022 08 02.
Article in English | MEDLINE | ID: mdl-35918090
SELECTION OF CITATIONS
SEARCH DETAIL